CNMD's revenue has flattened, with 2026Q3 sales of $335.6M down 0.9% year over year after peaking near $373.5M in 2025Q4, suggesting limited organic growth momentum.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $1.04+4.0% vs $1.00 | $336M-0.2% vs $336M |
Q3 2026 Jul 29, 2026 | $1.38+24.3% vs $1.11 | $343M+1.7% vs $338M |
Q2 2026 Apr 29, 2026 | $0.89+8.5% vs $0.82 | $317M+2.1% vs $311M |
Q1 2026 Jan 28, 2026 | $1.43+8.3% vs $1.32 | $373M+1.7% vs $367M |
On October 06, 2026, Conmed Corp (CNMD) shares fell 6.0% to a current price of $44.48, marking a significant decline in the context of a 52-week range of $31.44
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This confer.
CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.
Canada Pension Plan Investment Board purchased a new position in CONMED Corporation (NYSE: CNMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,800 shares of the company's stock, valued at approximately $452,000. Other institutional investors also recently modified
Benchmark CNMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CONMED Corporation (CNMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $51.50 | $1.54B | 21.13 | 5.16% | 5.36% | 7.07% | 1.54% | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $87.23 | $5.2B | 32.89 | 11.66% | 9.94% | 9.65% | — | |
| $80.89 | $1.85B | 29.47 | 13.53% | 23.51% | 15.33% | 0.98% | |
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% |
CONMED Corporation (CNMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CONMED Corporation (CNMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Jul 29, 2026·SEC
Jun 17, 2026·SEC
Get notified when CNMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CONMED Corporation (CNMD) stock FAQ — growth, dividends, profitability & financials explained
CONMED Corporation (CNMD) reported $1.37B in revenue in fiscal year 2025, which is also its trailing twelve months. That is 994% more than the $125.6M of fiscal year 1996.
CONMED Corporation (CNMD) grew revenue by 1.7% over the trailing twelve months, compared with the twelve months before.
Yes. CONMED Corporation (CNMD) earned $73.4M in net income over the trailing twelve months (a 5.4% net margin).
Yes. CONMED Corporation (CNMD) pays a dividend that yields 1.54% at the current price, a moderate yield.
CONMED Corporation (CNMD) had a return on equity (ROE) of 7.1% over the trailing twelve months. That is below the market's typical 10-15%.
CONMED Corporation (CNMD) generated $132.7M in free cash flow over the trailing twelve months.
